Viridian Therapeutics (VRDN)
NASDAQ:VRDN
VRDN Stock Chart & Stats
$18.84
-$0.50(-1.51%)
At close: 4:00 PM EST
$18.84
-$0.50(-1.51%)
Day’s Range― - ―
52-Week Range$9.90 - $34.29
Previous CloseN/A
Volume140.31K
Average Volume (3M)814.59K
Market Cap
$1.93B
Enterprise Value$1.44B
Total Cash (Recent Filing)$874.65M
Total Debt (Recent Filing)$50.69M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
May 12, 2026EPS Estimate
-1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares Outstanding102,206,570
10 Day Avg. Volume1,087,693
30 Day Avg. Volume814,586
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)3.65
Price to Sales (P/S)37.25
P/FCF Ratio-9.53
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue20.28
Enterprise Value/Gross Profit20.37
Enterprise Value/Ebitda-4.30
Forecast
1Y Price Target
$36.38Price Target Upside93.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-3.82
Revenue Forecast (FY)$73.71M
Bulls Say, Bears Say
Bulls Say
Administration ConvenienceA low-volume, self-administered autoinjector enables at-home subcutaneous treatment, which may attract a meaningful subgroup of patients and help expand the overall market.
Clinical DifferentiationVeligrotug has shown efficacy comparable to the current standard-of-care while requiring a shorter treatment course and demonstrated a meaningful reduction in double vision, which could provide a commercial edge.
Competitive LandscapeA late-stage failure of a rival thyroid eye disease therapy removed a competing drug class, reducing competitive pressure on Viridian's development programs.
Bears Say
Dose-response And Commercial RiskEvidence of receptor saturation and absence of a clear dose-response could bias use toward lower-frequency dosing, reducing revenue per treated patient and constraining pricing power.
Efficacy Versus BenchmarkSubcutaneous elegrobart showed weaker efficacy than the leading intravenous therapy, which could limit its ability to displace existing treatments.
Trial Variability And Regulatory RiskHigh placebo responses and inconsistent secondary endpoints in pivotal data reduce confidence in predictable clinical benefit and make positive results in the second pivotal trial critical for approval.
Viridian Therapeutics News
VRDN FAQ
What was Viridian Therapeutics’s price range in the past 12 months?
Viridian Therapeutics lowest stock price was $9.90 and its highest was $34.29 in the past 12 months.
What is Viridian Therapeutics’s market cap?
Viridian Therapeutics’s market cap is $1.93B.
When is Viridian Therapeutics’s upcoming earnings report date?
Viridian Therapeutics’s upcoming earnings report date is May 12, 2026 which is in 36 days.
How were Viridian Therapeutics’s earnings last quarter?
Viridian Therapeutics released its earnings results on Feb 26, 2026. The company reported -$1.08 earnings per share for the quarter, missing the consensus estimate of -$0.98 by -$0.1.
Is Viridian Therapeutics overvalued?
According to Wall Street analysts Viridian Therapeutics’s price is currently Undervalued.
Does Viridian Therapeutics pay dividends?
Viridian Therapeutics does not currently pay dividends.
What is Viridian Therapeutics’s EPS estimate?
Viridian Therapeutics’s EPS estimate is -1.06.
How many shares outstanding does Viridian Therapeutics have?
Viridian Therapeutics has 102,206,570 shares outstanding.
What happened to Viridian Therapeutics’s price movement after its last earnings report?
Viridian Therapeutics reported an EPS of -$1.08 in its last earnings report, missing expectations of -$0.98. Following the earnings report the stock price went up 1.9%.
Which hedge fund is a major shareholder of Viridian Therapeutics?
Currently, no hedge funds are holding shares in VRDN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viridian Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.38 (93.12% Upside)
$36.38 (93.12% Upside)
Hedge Fund Trend
Increased
By 891.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
News Sentiment
Bullish
Bullish news 64%
Bearish news 36%
Bearish news 36%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.56%
12-Months-Change
Fundamentals
Return on Equity
-58.44%
Trailing 12-Months
Asset Growth
21.15%
Trailing 12-Months
Company Description
Viridian Therapeutics
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
VRDN Stock 12 Month Forecast
Average Price Target
$36.38
▲(93.12% Upside)
Technical Analysis
Dianthus Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
3.89% Insiders
25.55% Mutual Funds
47.87% Other Institutional Investors
8.55% Public Companies and Individual Investors